122 related articles for article (PubMed ID: 1674155)
21. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.
Awad AG; Voruganti LN; Heslegrave RJ; Hogan TP
Int Clin Psychopharmacol; 1996 May; 11 Suppl 2():55-9. PubMed ID: 8803661
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
23. [Profile of the action of neuroleptics in deficit schizophrenia].
Vanelle JM
Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
[TBL] [Abstract][Full Text] [Related]
24. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
[TBL] [Abstract][Full Text] [Related]
25. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
26. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
[TBL] [Abstract][Full Text] [Related]
27. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia.
Kim JH; Kim SY; Ahn YM; Kim YS
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):301-5. PubMed ID: 16309807
[TBL] [Abstract][Full Text] [Related]
28. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
Naber D
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
[TBL] [Abstract][Full Text] [Related]
29. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
[TBL] [Abstract][Full Text] [Related]
30. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
[TBL] [Abstract][Full Text] [Related]
31. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.
Goldberg TE; Weinberger DR
J Clin Psychiatry; 1996; 57 Suppl 9():62-5. PubMed ID: 8823353
[TBL] [Abstract][Full Text] [Related]
32. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
Glazer WM; Ereshefsky L
J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
[TBL] [Abstract][Full Text] [Related]
33. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
Stanković Z; Britvić D; Vuković O; Ille T
Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
[TBL] [Abstract][Full Text] [Related]
34. Pathophysiology and treatment of negative symptoms.
Villeneuve A
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S53-8. PubMed ID: 7533052
[TBL] [Abstract][Full Text] [Related]
35. Predictors of subjective and objective quality of life in outpatients with schizophrenia.
Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437
[TBL] [Abstract][Full Text] [Related]
36. [Incidence of the deficit form in refractory schizophrenia].
Samuelian JC
Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
[TBL] [Abstract][Full Text] [Related]
37. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Kopala LC; Fredrikson D; Good KP; Honer WG
Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
[No Abstract] [Full Text] [Related]
38. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders.
Svestka J; Bitter I
Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():95-116. PubMed ID: 17262005
[TBL] [Abstract][Full Text] [Related]
39. Depot neuroleptic therapy: clinical considerations.
Remington GJ; Adams ME
Can J Psychiatry; 1995 Apr; 40(3 Suppl 1):S5-11. PubMed ID: 7627927
[TBL] [Abstract][Full Text] [Related]
40. Clozapine maintenance therapy in schizophrenia.
Gaszner P; Makkos Z
Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
